Estimated EarlyCDT-Lung test performance characteristics 6 months, 1 year and 2 years after randomisation
| Test-positive | Test-negative | Sensitivity | Specificity | Positive predictive value | Negative predictive value | |
| Subjects | 598 | 5489 | ||||
| Stage of lung cancer 6 months after randomisation (post hoc) | ||||||
| I/II | 7 (1.2) | 2 (0.0) | 77.8 (40.0–97.2) | 90.3 (89.5–91.0) | 1.2 (0.5–2.4) | 100.0 (99.9–100.0) |
| III/IV | 5 (0.8) | 8 (0.2) | 38.5 (13.9–68.4) | 90.2 (89.5–91.0) | 0.8 (0.3–1.9) | 99.9 (99.7–99.9) |
| I–IV | 12 (2.0) | 10 (0.2) | 54.6 (32.2–75.6) | 90.3 (89.6–91.1) | 2.0 (1.0–3.5) | 99.8 (99.7–99.9) |
| Stage of lung cancer 1 year after randomisation (post hoc) | ||||||
| I/II | 9 (1.5) | 4 (0.1) | 69.2 (38.6–90.9) | 90.3 (89.5–91.0) | 1.5 (0.7–2.8) | 99.9 (99.8–100.0) |
| III/IV | 6 (1.0) | 14 (0.2) | 30.0 (11.9–54.3) | 90.2 (89.5–91.0) | 1.0 (0.4–2.2) | 99.7 (99.6–99.9) |
| I–IV | 15 (2.5) | 18 (0.3) | 45.5 (28.1–63.6) | 90.4 (89.6–91.1) | 2.5 (1.4–4.1) | 99.7 (99.5–99.8) |
| Stage of lung cancer 2 years after randomisation | ||||||
| I/II | 12 (2.0) | 11 (0.2) | 52.2 (30.6–73.2) | 90.3 (89.6–91.1) | 2.0 (1.0–3.5) | 99.8 (99.6–99.9) |
| III/IV | 6 (1.0) | 27 (0.5) | 18.2 (7.0–35.5) | 90.2 (89.4–91.0) | 1.0 (0.4–2.2) | 99.5 (99.3–99.7) |
| I–IV | 18 (3.0) | 38 (0.7) | 32.1 (20.3–46.0) | 90.4 (89.6–91.1) | 3.0 (1.8–4.7) | 99.3 (99.1–99.5) |
Data are presented as n, n (%) or % (95% CI). Absolute risk reduction of late-stage lung cancer diagnosis 2 years after randomisation was 0.31%. The number needed to screen to prevent one late-stage lung cancer diagnosis 2 years after randomisation was 325 (95% CI 13–637).